; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial.
Elucidation of mitochondrial effects by tetrahydroaminoacridine
(tacrine) in rat, dog, monkey and human hepatic parenchymal cells.
Among these drugs is tacrine (tetrahydroaminoacridine
Last March, an FDA advisory panel recommended against the approval of tetrahydroaminoacridine
(THA), a potential Alzheimer treatment that inhibits the breakdown of acetylcholine (SN: 3/23/91, p.180).
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine
in long-term treatment of senile dementia, Alzheimer type.
The anticholinesterase drug tacrine (tetrahydroaminoacridine
) has been shown to improve cognitive function in between 30 and 40% of patients with Alzheimer's disease (AD) [1, 2].
In announcing its conclusion last week, the panel cited a lack of convincing scientific evidence demonstrating the efficacy and safety of the drug, known as tetrahydroaminoacridine
Such a treatment exists in the form of tacrine (THA; tetrahydroaminoacridine
The study focused on tetrahydroaminoacridine
(THA), a compound that inhibits a crucial brain enzyme required to break down the neurotransmitter acetylcholine (SN: 11/15/86, p.308).
Seventy-nine patients with probable Alzheimer's disease were enrolled into a double-blind, placebo-controlled cross-over study to assess the therapeutic effect and safety of THA (tetrahydroaminoacridine
; tacrine) without concomitant lecithin administration.
Enthusiasm over the potential of tetrahydroaminoacridine
(THA) as a treatment for Alzheimer's disease waned last fall, amid questions about the original research and the suspension of a large clinical trial because of serious side effects (SN: 11/7/87, p.292).
If new agents such as tetrahydroaminoacridine
(THA)  are introduced, the demand for assessment is likely to grow further.